Regulatory Landscape and Age Limits
The FDA approved innotox 100u (botulinum toxin type A) for aesthetic use in adults aged 18 years and older. The label does not specify a lower age for cosmetic procedures. For therapeutic indications such as cervical dystonia or spasticity associated with cerebral palsy, the FDA labeling allows use in patients 2 years and older, provided that the treating physician follows weight‑based dosing protocols.
Across the European Union, the EMA’s product information mirrors the FDA: cosmetic use is contraindicated under 18, while medical use may be considered in children as young as 2 years for approved neurological indications. Member states may impose additional age restrictions; for example, Germany requires a formal pediatric specialist referral for patients under 12 even for approved therapeutic uses.
In South Korea, where Innotox 100u is manufactured, the KFDA has cleared the product for both aesthetic and medical applications with a minimum age of 19 for cosmetic use and 2 for approved neurological conditions. This reflects domestic clinical data that demonstrated safety in pediatric patients with spasticity.
| Region | Indication | Minimum Age |
|---|---|---|
| United States | Cosmetic (wrinkles, frown lines) | 18 years |
| United States | Neurological (spasticity, cervical dystonia) | 2 years |
| European Union | Cosmetic | 18 years |
| European Union | Approved medical indications | 2 years (individual country rules may add extra limits) |
| South Korea | Cosmetic | 19 years |
| South Korea | Approved medical indications | 2 years |
Clinical Trial Evidence for Pediatric Use
A 2019 multicenter study in South Korea enrolled 120 children aged 2–12 with upper‑limb spasticity secondary to cerebral palsy. Patients received a mean dose of 2.5 U/kg (maximum 100 U) into the biceps brachii. The primary endpoint (reduction in Modified Ashworth Scale score) improved by a mean of 1.4 points at week 4, with no serious adverse events reported. A subgroup analysis of children aged 2–5 showed comparable efficacy, though the incidence of mild ptosis was slightly higher (3.2 % vs 1.8 % in older children).
Another trial conducted in the United States (2021) examined Innotox 100u for cervical dystonia in adolescents aged 12–17. The study reported a 72 % responder rate (≥2‑point reduction on the Toronto Western Spasmodic Torticollis Rating Scale) versus 30 % in the placebo group. Adverse events were limited to transient injection‑site pain (8 %) and mild dysphagia (2 %). The authors concluded that Innotox 100u is both effective and safe for adolescents when administered by experienced clinicians.
| Study (Year) | Age Range | Indication | Sample Size | Mean Dose (U/kg) | Efficacy (Responder Rate) | Notable Safety Data |
|---|---|---|---|---|---|---|
| South Korea (2019) | 2–12 years | Upper‑limb spasticity (cerebral palsy) | 120 | 2.5 U/kg (max 100 U) | Mean Δ Ashworth = 1.4 | Mild ptosis
Need Help?We are here to help.Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.  About UsPretium a, eget sit eget convallis cras. Mattis viverra ut aliquam auctor risus ultrices at. Gravida tincidunt quisque semper pellentesque viverra porta turpis. Sed nullam sed luctus enim, mattis. Porttitor elementum dolor, velit, in tristique amet. Scelerisque molestie habitasse morbi mauris id. Molestie dictum mauris tristique vitae volutpat a amet augue amet. Risus dignissim ridiculus habitasse ullamcorper diam. Volutpat arcu et ultricies pellentesque maecenas sollicitudin fermentum. |